BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells $350,300.86 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN traded down $0.72 during trading hours on Friday, hitting $64.88. 77,189 shares of the stock were exchanged, compared to its average volume of 1,823,237. BioMarin Pharmaceutical Inc. has a 52-week low of $64.56 and a 52-week high of $99.56. The firm’s fifty day moving average price is $70.85 and its 200 day moving average price is $79.28. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The company has a market cap of $12.36 billion, a P/E ratio of 38.85, a P/E/G ratio of 0.66 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm had revenue of $746.00 million for the quarter, compared to analysts’ expectations of $703.37 million. During the same quarter last year, the firm posted $0.26 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 28.4% on a year-over-year basis. As a group, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BMRN. William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Bank of America lowered their price target on BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Sanford C. Bernstein decreased their price objective on BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, September 17th. Wells Fargo & Company decreased their price objective on BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating for the company in a report on Tuesday, September 17th. Finally, Barclays decreased their price objective on BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a report on Friday, October 4th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Innealta Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. BOKF NA acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $31,000. Quent Capital LLC boosted its holdings in shares of BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares during the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $47,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.